{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:27Z","timestamp":1740126447873,"version":"3.37.3"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T00:00:00Z","timestamp":1406160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Adacolumn Business Univ-EU"},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart-Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"King Oscar II Jubilee Foundation"},{"DOI":"10.13039\/100007464","name":"Torsten and Ragnar S\u00f6derbergs Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007464","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mats Kleeberg Foundation"},{"DOI":"10.13039\/501100006129","name":"King Gustaf V's and Queen Victoria's Freemasons' Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,24]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Sarcoidosis is a systemic, inflammatory disorder, which in a proportion of patients runs a chronic progressive course despite immunosuppressive treatment. Therapeutic granulocyte and monocyte apheresis (GMA) has been shown to be an effective treatment option for other systemic inflammatory disorders, but has not yet been investigated in sarcoidosis. The aim of this study was to evaluate the response to GMA in sarcoidosis. Seven patients with sarcoidosis refractory to standard immunosuppressive therapy received 10 GMA sessions. All patients underwent chest X-ray, spirometry, a Chronic Respiratory Disease Questionnaire (CRQ-SAS), blood tests and bronchoscopy with bronchoalveolar lavage (BAL) before treatment and at 2\u20134 weeks and 3 months (except bronchoscopy) after the last treatment session. Bronchoalveolar lavage fluid (BALF) cell differential counts were recorded and T cells from blood and BALF were analysed for markers of activity, differentiation and T regulatory function. Compared to baseline, five of seven patients reported an improvement in dyspnoea score. In BALF there was an increase in the percentage of macrophages and a decrease in the percentage of lymphocytes and CD4+\/FoxP3+T cells. Furthermore, the decrease in BALF CD4+\/FoxP3+T cells correlated significantly with an improvement in dyspnoea score. In peripheral blood there was a statistically significant increase in the percentage of CD4+\/CD27\u2212T cells and a trend towards an initial increase in the percentage of CD4+\/FoxP3+T cells, followed by a statistically significant decrease. The effects of GMA on regulatory T cells are consistent with those observed in other inflammatory disorders and could potentially translate into a clinical benefit.<\/jats:p>","DOI":"10.1111\/cei.12360","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T11:07:15Z","timestamp":1398683235000},"page":"712-719","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action"],"prefix":"10.1093","volume":"177","author":[{"given":"H H","family":"Olsen","sequence":"first","affiliation":[{"name":"Respiratory Medicine Unit, Department of Medicine and CMM, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Muratov","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Cederlund","sequence":"additional","affiliation":[{"name":"Department of Radiology, Huddinge and Department of Clinical Science, Intervention and Technology, Division of Medical Imaging and Technology, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Lundahl","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Eklund","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Unit, Department of Medicine and CMM, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Grunewald","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Unit, Department of Medicine and CMM, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,7,24]]},"reference":[{"key":"2021122010042218800_cei12360-bib-0001","first-page":"736","article-title":"Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2021122010042218800_cei12360-bib-0002","first-page":"191","article-title":"Neutrophil phagocytosis in sarcoidosis. Reduced C3b receptor-mediated phagocytosis in active and silent sarcoidosis","volume":"60","author":"Schmekel","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"2021122010042218800_cei12360-bib-0003","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.humimm.2012.05.005","article-title":"Changed phagocytic activity and pattern of Fc\u03b3 and complement receptors on blood monocytes in sarcoidosis","volume":"73","author":"Dubaniewicz","year":"2012","journal-title":"Hum Immunol"},{"key":"2021122010042218800_cei12360-bib-0004","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2249.2008.03791.x","article-title":"Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease","volume":"155","author":"Fortunati","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2021122010042218800_cei12360-bib-0005","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1055\/s-2007-991521","article-title":"Bronchoalveolar lavage in sarcoidosis","volume":"28","author":"Drent","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"2021122010042218800_cei12360-bib-0006","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2021122010042218800_cei12360-bib-0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jca.1000","article-title":"Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study","volume":"16","author":"Shimoyama","year":"2001","journal-title":"J Clin Apher"},{"key":"2021122010042218800_cei12360-bib-0008","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1365-2036.2004.02288.x","article-title":"Granulocyte aphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study","volume":"20","author":"Dom\u00e8nech","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122010042218800_cei12360-bib-0009","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.dld.2004.08.004","article-title":"Clinical evaluation of granulocyte\/monocyte apheresis therapy for active ulcerative colitis","volume":"36","author":"Kanke","year":"2004","journal-title":"Dig Liver Dis"},{"key":"2021122010042218800_cei12360-bib-0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/00365520600979369","article-title":"Granulocyte, monocyte\/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia","volume":"42","author":"Ljung","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"2021122010042218800_cei12360-bib-0011","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/jcgh.2003.50005","article-title":"Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, un-controlled, pilot study","volume":"1","author":"Hanai","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122010042218800_cei12360-bib-0012","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000080079","article-title":"Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis","volume":"70","author":"Hanai","year":"2004","journal-title":"Digestion"},{"key":"2021122010042218800_cei12360-bib-0013","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10620-009-0845-x","article-title":"Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis","volume":"55","author":"Habermalz","year":"2010","journal-title":"Dig Dis Sci"},{"key":"2021122010042218800_cei12360-bib-0014","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1365-2036.2010.04490.x","article-title":"Systematic review: granulocyte\/monocyte adsorptive apheresis for ulcerative colitis","volume":"32","author":"Thanaraj","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122010042218800_cei12360-bib-0015","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00384-011-1193-9","article-title":"The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis","volume":"26","author":"Zhu","year":"2011","journal-title":"Int J Colorectal Dis"},{"key":"2021122010042218800_cei12360-bib-0016","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/rheumatology\/keh701","article-title":"Adsorptive granulocyte\/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial","volume":"44","author":"Sanmart\u00ed","year":"2005","journal-title":"Rheumatology (Oxf)"},{"key":"2021122010042218800_cei12360-bib-0017","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1744-9987.12113","article-title":"Granulocyte and monocyte adsorption apheresis for refractory skin diseases due to activated neutrophils, psoriasis, and associated arthropathy","volume":"17","author":"Sakanoue","year":"2013","journal-title":"Ther Apher Dial"},{"key":"2021122010042218800_cei12360-bib-0018","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.dld.2005.01.014","article-title":"Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus","volume":"37","author":"Sawada","year":"2005","journal-title":"Dig Liver Dis"},{"key":"2021122010042218800_cei12360-bib-0019","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2249.2010.04279.x","article-title":"The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review","volume":"163","author":"Hanai","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"2021122010042218800_cei12360-bib-0020","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000341801","article-title":"Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease","volume":"39","author":"C Leitner","year":"2012","journal-title":"Transfus Med Hemother"},{"key":"2021122010042218800_cei12360-bib-0021","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2249.2009.03904.x","article-title":"The expression profile of functional regulatory T cells, CD4+CD25high+\/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease","volume":"156","author":"Kamikozuru","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2021122010042218800_cei12360-bib-0022","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3748\/wjg.14.1521","article-title":"Regulatory T cells in patients with inflammatory bowel diseases treated with Adacolumn granulocytapheresis","volume":"14","author":"Cuadrado","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2021122010042218800_cei12360-bib-0023","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1007\/s10620-006-9560-z","article-title":"Demonstration of low-regulatory CD25high+CD4+ and high-pro-inflammatory CD28-CD4+ T-cells subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis","volume":"52","author":"Yokoyama","year":"2007","journal-title":"Dig Dis Sci"},{"key":"2021122010042218800_cei12360-bib-0024","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00002281-200307000-00010","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis","volume":"15","author":"Gambineri","year":"2003","journal-title":"Curr OpinRheumatol"},{"key":"2021122010042218800_cei12360-bib-0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nri821","article-title":"CD4+CD25+ suppressor T cells: more questions than answers","volume":"2","author":"Shevach","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"2021122010042218800_cei12360-bib-0026","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/eji.200526189","article-title":"Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single cell level","volume":"35","author":"Roncador","year":"2005","journal-title":"Eur J Immunol"},{"key":"2021122010042218800_cei12360-bib-0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2249.2008.03609.x","article-title":"Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis","volume":"152","author":"Idali","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"2021122010042218800_cei12360-bib-0028","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/thx.41.8.629","article-title":"Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis","volume":"41","author":"Eklund","year":"1986","journal-title":"Thorax"},{"key":"2021122010042218800_cei12360-bib-0029","first-page":"142","article-title":"Aspects on the alveolar accumulation of T cells in sarcoidosis","volume":"9","author":"Grunewald","year":"1992","journal-title":"Sarcoidosis"},{"key":"2021122010042218800_cei12360-bib-0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2796.2012.02543.x","article-title":"T-cell phenotypes in bronchoalveolar lavage fluid, blood and lymph nodes in pulmonary sarcoidosis \u2013 indication for an airborne antigen as the triggering factor in sarcoidosis","volume":"272","author":"Darlington","year":"2012","journal-title":"J Intern Med"},{"key":"2021122010042218800_cei12360-bib-0031","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.4049\/jimmunol.139.5.1589","article-title":"Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen","volume":"139","author":"van Lier","year":"1987","journal-title":"J Immunol"},{"key":"2021122010042218800_cei12360-bib-0032","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.4049\/jimmunol.149.10.3208","article-title":"CD27, a member of the nerve growth factor receptor family, is preferentially expressed on CD45Ra+ CD4 T cell clones and involved in distinct immunoregulatory functions","volume":"149","author":"Sugita","year":"1992","journal-title":"J Immunol"},{"key":"2021122010042218800_cei12360-bib-0033","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4049\/jimmunol.147.1.29","article-title":"A soluble form of the human T-cell differentiation antigen CD 27 is released after triggering of the TCR \/CD3 complex","volume":"147","author":"Hintzen","year":"1991","journal-title":"J Immunol"},{"key":"2021122010042218800_cei12360-bib-0034","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1164\/ajrccm\/148.3.643","article-title":"Soluble and cellular markers of T cell activation in patients with pulmonary sarcoidosis","volume":"148","author":"Hol","year":"1993","journal-title":"Am Rev Respir Dis"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12360","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/177\/3\/712\/41789808\/cei12360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/177\/3\/712\/41789808\/cei12360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T12:32:44Z","timestamp":1689165164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/177\/3\/712\/6421199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,24]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,7,24]]},"published-print":{"date-parts":[[2014,7,24]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12360","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"type":"print","value":"0009-9104"},{"type":"electronic","value":"1365-2249"}],"subject":[],"published-other":{"date-parts":[[2014,9]]},"published":{"date-parts":[[2014,7,24]]}}}